title: Current and potential epigenetic targets in multiple myeloma.
abstract: Despite recent advances in therapy, subgroups of multiple myeloma continue to have a poor prognosis. Numerous epigenetic changes have been described and occur as both etiologic and secondary events, making myeloma a good disease in which to understand the role of epigenetic therapies. Here, we describe a number of current and potential epigenetic targets in myeloma.
authors.affiliation: Centre for Myeloma Research, Institute of Cancer Research, 15 Cotswold Rd, Sutton, SM2 5NG, UK.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Pawlyn
authors.forename: Martin F
authors.initials: MF
authors.lastname: Kaiser
authors.forename: Faith E
authors.initials: FE
authors.lastname: Davies
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D000107:Acetylation / Q000187:drug effects; D001402:B-Lymphocytes / Q000166:cytology; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D019175:DNA Methylation / Q000187:drug effects; D044127:Epigenesis, Genetic / Q000235:genetics*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D056466:Histone Demethylases / Q000037:antagonists & inhibitors; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase / Q000037:antagonists & inhibitors; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics* / Q000628:therapy*
chemical_list: D056572:Histone Deacetylase Inhibitors; D056466:Histone Demethylases; D000076983:Histone Methyltransferases; D004248:DNA (Cytosine-5-)-Methyltransferases; D011495:Histone-Lysine N-Methyltransferase